The SARS-CoV-2 Vaccine Pipeline: an Overview
暂无分享,去创建一个
Maria Elena Bottazzi | Peter J Hotez | Ulrich Strych | P. Hotez | M. Bottazzi | Wen-Hsiang Chen | U. Strych | Wen-Hsiang Chen
[1] W. Raub. From the National Institutes of Health. , 1990, JAMA.
[2] Jing Zhao,et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.
[3] E. Holmes,et al. Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China , 2020, bioRxiv.
[4] Fei Deng,et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin , 2020, bioRxiv.
[5] Elissa M. Hudspeth,et al. Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate , 2017, Journal of Pharmaceutical Sciences.
[6] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[7] P. Vollmar,et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany , 2020, The New England journal of medicine.
[8] P. Hotez,et al. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome , 2012, Expert review of vaccines.
[9] Christian Drosten,et al. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells , 2020, bioRxiv.
[10] M. Frieman,et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice , 2014, Vaccine.
[11] Elissa M. Hudspeth,et al. Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate , 2014, Human vaccines & immunotherapeutics.